Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vancomycin. A new old agent.

M J Ingerman1, J Santoro

  • 1Medical College of Pennsylvania, Philadelphia.

Infectious Disease Clinics of North America
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Vancomycin is gaining renewed interest due to rising resistant gram-positive infections and enhanced drug purity. This summary covers its activity, use, dosing, and side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A quality improvement strategy to reduce unintended extubation in the very low birth weight infant: A case report.

Journal of neonatal-perinatal medicine·2024
Same author

1H, 13C, and 15N resonance assignments of the N-terminal domain of human Tubulin Binding Cofactor C.

Biomolecular NMR assignments·2010
Same author

The solution structure and dynamics of human pancreatic ribonuclease determined by NMR spectroscopy provide insight into its remarkable biological activities and inhibition.

Journal of molecular biology·2008
Same author

Femtosecond Ti:Sapphire Oscillator Electro-Optically Cavity Dumped at 50 kHz.

Applied optics·2008
Same author

The validity and accuracy of the Work Productivity and Activity Impairment questionnaire--irritable bowel syndrome version (WPAI:IBS).

Alimentary pharmacology & therapeutics·2004
Same author

Observation of an exotic S = +1 baryon in exclusive photoproduction from the deuteron.

Physical review letters·2004
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Emergence of antibiotic-resistant gram-positive pathogens necessitates re-evaluation of existing antimicrobials.
  • Improvements in vancomycin purification have enhanced its therapeutic profile.
  • Vancomycin remains a critical agent for treating serious Gram-positive bacterial infections.

Purpose of the Study:

  • To provide a comprehensive overview of vancomycin.
  • To summarize current knowledge on vancomycin's antimicrobial activity, pharmacokinetics, and clinical applications.
  • To update information on vancomycin dosing, administration, and adverse effects.

Main Methods:

  • Literature review of existing studies and clinical data on vancomycin.
  • Synthesis of information regarding vancomycin's mechanism of action and spectrum of activity.

Related Experiment Videos

  • Analysis of pharmacokinetic and pharmacodynamic data to inform dosing recommendations.

    • Main Results:

    • Vancomycin exhibits potent activity against methicillin-resistant Staphylococcus aureus (MRSA) and other resistant Gram-positive bacteria.
    • Pharmacokinetic data support specific dosing regimens for achieving optimal therapeutic levels.
    • Clinical efficacy is well-established for various infections, including endocarditis, meningitis, and osteomyelitis.

    Conclusions:

    • Vancomycin remains a cornerstone therapy for infections caused by susceptible Gram-positive organisms, particularly resistant strains.
    • Optimized dosing and monitoring are crucial for maximizing efficacy and minimizing toxicity.
    • Continued research and vigilance are necessary to address evolving resistance patterns and ensure effective vancomycin use.